|Outcome||Relative effect 95%CI||LoD||Trt. better when||I2||k (RCT/OBS)||Bayesian probability||Overall ROB||Publication bias||Degree of certainty||Endpoint importance||Published MA|
|death||0.88 [0.42, 1.81]||< 1||0%||4 studies (4/-)||64.0 %||some concern||not evaluable||moderate||crucial||-|
|clinical improvement||8.18 [0.32, 209.71]||> 1||82%||3 studies (3/-)||89.5 %||high||not evaluable||low||important||-|
|Influenza-like infection||1.54 [0.62, 3.78]||< 1||0%||1 study (1/-)||17.5 %||low||not evaluable||high||important||-|
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.